Financial Tables | Printer Friendly Version 

Highlights:  

  • Revenue of $1.76 billion represents 5% reported growth year-over-year; and up 10% on a core(1) basis.
  • GAAP net income of $352 million with earnings per share (EPS) of $1.19, up 28% from the first quarter of 2022.
  • Non-GAAP(2) net income of $406 million with EPS of $1.37, up 13% from the first quarter of 2022.
  • Full-year revenue has been raised and is now expected to be in the range of $7.03 billion to $7.10 billion, representing reported growth of 2.7% to 3.7% and core(1) growth of 5.5% to 6.5%.  Fiscal year 2023 non-GAAP(3) EPS has also been raised and is now estimated to be in the range of $5.65 to $5.70.
  • Second-quarter revenue expected to be in the range of $1.655 billion to $1.680 billion with non-GAAP(3) EPS of $1.24 to $1.27. 

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.76 billion for the first quarter ended January 31, 2023, an increase of 5% compared to the first quarter of 2022 and up 10% on a core(1) basis.

First-quarter GAAP net income was $352 million, or $1.19 per share. This compares with $283 million, or 93 cents per share, in the first quarter of fiscal year 2022. Non-GAAP(2) net income was $406 million, or $1.37 per share during the quarter, compared with $368 million or $1.21 per share during the first quarter a year ago.

“The Agilent team delivered an excellent start to 2023 with broad-based growth across our end markets and geographic regions,” said Agilent President and CEO Mike McMullen. “These positive results reflect the resiliency and durability of our diversified business and put us in a solid position for the year ahead.”

Financial Highlights

Life Sciences and Applied Markets Group

Agilent’s Life Sciences and Applied Markets Group (LSAG) reported first-quarter revenue of $1.033 billion, a year-over-year increase of 6% (up 11% on a core(1) basis). LSAG’s operating margin for the quarter was 30.4%. 

Agilent CrossLab Group

The Agilent CrossLab Group (ACG) reported first-quarter revenue of $381 million, a year-over-year increase of 6% (up 13% on a core(1) basis). ACG’s operating margin for the quarter was 27.0%.

Diagnostics and Genomics Group

The Diagnostics and Genomics Group (DGG) reported first-quarter revenue of $342 million, a year-over-year increase of 1% (up 5% on a core(1) basis). DGG’s operating margin for the quarter was 17.2%.

Full Year and Second-Quarter Outlook

Full-year revenue has been raised and is now expected to be in the range of $7.03 billion to $7.10 billion, representing reported growth of 2.7% to 3.7% and core(1) growth of 5.5% to 6.5%.  Fiscal year 2023 non-GAAP(3) EPS guidance has also been raised and is now estimated to be in the range of $5.65 to $5.70.

The outlook for second-quarter revenue is expected to be in a range of $1.655 billion to $1.680 billion. Second-quarter non-GAAP(3) earnings guidance is expected to be in the range of $1.24 to $1.27 per share.

The outlook is based on forecasted currency exchange rates.

Conference Call

Agilent’s management will present additional details regarding the company’s first-quarter 2023 financial results on a conference call with investors today at 1:30 p.m. PST. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the “Q1 2023 Agilent Technologies Inc. Earnings Conference Call” link on the Agilent Investor Relations website. The webcast will remain on the company site for 90 days.